Note that some links may require registration or subscription.
Eli Lilly paused the phase III trial of its monoclonal antibody treatment for COVID-19 — a similar medicine to what President Trump received — for safety concerns. (CNBC)
And federal inspectors identified quality control problems at a pharmaceutical plant that’s ramping up to manufacture one of the company’s drugs if approved, Reuters reported.
Johnson & Johnson said it will take a few days at least to hear from a safety monitoring panel about its late-stage COVID-19 vaccine trial that was halted this week over an unexplained illness in a trial participant. (Reuters)
As of Wednesday at 8:00 a.m. EST, the unofficial COVID-19 toll included 7,859,365 cases and 215,914 deaths. That’s up 54,705 cases and 825 deaths from this time a day ago.
Forty states have seen a week-to-week increase in coronavirus infections. (Washington Post)
Meanwhile, COVID-19 hospitalizations have topped 35,000, their highest level in nearly 6 weeks. (Wall Street Journal)
And Europe reported a record-high 700,000 COVID-19 cases last week, according to the WHO. (NPR)
Only 50% of Americans are willing to get an FDA-backed COVID-19 vaccine — down from 66% in July — a Gallup poll showed.
Roche announced plans to launch a SARS-CoV-2 laboratory antigen test to support high-volume testing of suspected COVID-19 patients.
People of color should be over-represented in COVID-19 vaccine trials, an ED doctor argued. (MarketWatch)
The FDA is resisting pressure from the Trump administration to refer to emergency use authorization of a COVID-19 vaccine as a pre-licensure, according to Politico.
NIH launched a new study to evaluate whether promising treatments for COVID-19 warrant testing in large clinical trials.
The first death from COVID-19 reinfection was reported in The Netherlands. (CNN)
But while reinfections do occur, they’re exceedingly rare. (New York Times)
In unlit lab conditions, SARS-CoV-2 remained infectious on phone screens, stainless steel, and other surfaces for 28 days, researchers said. (BBC)
In other news: